TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 10/05/23

2023-10-05 12:43:14 ET Summary Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug candidate. The company ended the second quarter w...

2023-09-12 17:09:48 ET Summary Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 trials for Duchenne muscular dystrophy and Huntington's Disease. Wave has collaborations with GSK a...

2023-08-29 13:45:03 ET Summary Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuximab Soravtansine in the Japanese market. ImmunoGen's antibody drug conjugate - marketed and sold as ...

2023-08-28 07:12:00 ET More on ImmunoGen, Takeda, etc. ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen's ELAHERE Has Likely Blockbuster Potential ImmunoGen: Comprehensive MIRASOL Data Reinforces Elahere's Potential Takeda: Upside Ca...

2023-08-11 17:59:00 ET Summary Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products ...

2023-07-27 09:27:02 ET Takeda Pharmaceutical Company Limited (TAK) Q1 2023 Results Earnings Conference Call July 27, 2023, 06:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer An...

2023-07-17 15:06:06 ET Summary Turnstone Biologics Corp. has filed proposed terms for a $75.4 million IPO. The firm is developing drug treatment candidates for solid tumors and other cancer conditions. Turnstone Biologics' major partners have terminated their collaboration agr...

2023-07-09 09:15:00 ET Summary Moderna is setting up operations in Shanghai to develop and manufacture mRNA products for the Chinese market, investing up to $1 billion. F-star Therapeutics has formed a collaboration with Takeda to develop Fcab domains for immuno-oncology targets, ...

2023-07-01 01:55:50 ET Summary Adapt Biotechnologies comes with interesting core offerings in immune medicine. The firm's MRD segment is driving the bulk of sales upsides, backed by sales volumes of its immunoSEQ and clonoSEQ units. Looking forward, ADPT reiterates its full-ye...

2023-06-21 05:10:17 ET Summary Kamada Ltd. has potential catalysts for growth, capital attraction and regulatory tailwinds. The company's valuation appears attractive, with forward estimates suggesting a possible re-rating. Key risks center around the investment in 2x new manu...